Pay in 4 interest-free payments of $5.33 Learn more
Ships within 48 hours · Estimated delivery Aug 31 - Sep 5
10.1056/nejm199207023270104 N
In most cases, resistance training is encouraged if there are no medical contraindications
Sources Eli Lilly: Your weekly Zepbound routine FDA access data: Zepbound (tirzepatide) Prescribing Information starting dose 2.5 mg once weekly (accessdata.fda.gov) FDA access data: Updated Zepbound label confirming dose escalation schedule (accessdata.fda.gov) FDA access data: Highlights of prescribing info reaffirm starting and maintenance doses (accessdata.fda.gov) Journal (NEJM): SURMOUNT1 trial showing substantial sustained weight loss at 5, 10, and 15 mg doses (PubMed/NEJM) Journal (PubMed): Substudy of SURMOUNT1 with DXA body composition data (~21.3% loss) (PubMed) Journal (PubMed): 3-year SURMOUNT1 follow-up in obese and pre-diabetic participants durable weight loss & diabetes prevention (PubMed) FDA access data: Mounjaro Prescribing Information starting dose 2.5 mg once weekly for diabetes (accessdata.fda.gov) Journal (NEJM): Headtohead trial vs semaglutide showing superior reductions in weight & waist at week 72 (NEJM DOI) Journal (AppliedClinicalTrials): SURMOUNT5 Phase IIIb headtohead trial data confirming greater weight loss over 72 weeks (AppliedClinicalTrials) Reuters: Report on diabetes risk reduction trial94% reduction in progression, ~22.9% weight loss (Reuters) Time: FDA Approval of Zepbound for Weight Loss (Time) American College of Cardiology: Tirzepatide Once Weekly for the Treatment of Obesity SURMOUNT-1 (acc.org) People using drug Mounjaro sustain weight loss over three years, trial finds (The Guardian) The Guardian: Clinical Trails: A Study of Tirzepatide in Participants With Obesity or Overweight (SURMOUNT-1) (NIH Clinal Trials) Journal (PubMed): Tirzepatide Once Weekly for the Treatment of Obesity (PubMed) FDA Label: MOUNJARO (Tirzepatide Injection) Medication Guide FDA Label: ZEPBOUND (Tirzepatide Injection) Medication Guide Important Medical Information and Disclaimers Important Current Status Update : On March 19, 2025, the FDA ended enforcement discretion for compounded tirzepatide
I became chronically ill about 12 years ago
